AzTrials
AzTrials

Atypical Cognitive DisordersASLDEM DSNCT02058043

Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET

An observational study of Atypical Cognitive Disorders, run by Rennes University Hospital at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

DESCRIPTION OF RELATED QUESTION Cognitive disorders are frequently encountered and present a major public health problem given the aging of the population. There is not one, but several neurodegenerative pathologies individual differentiated. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atypical Cognitive Disorders
How many people
1 participants
Where
1 siteFrance
Study dates
Nov 2012to Dec 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients presenting with atypical cognitive disorders

Who may be able to join

  • Male and females over 18 years of age
  • Patients presenting with atypical cognitive disorders, clinically and through neuropsychological tests, justifying the prescription by a specialist doctor of a brain MRI and FDG-PET and lie within the context of the recommendations of the HAS.
  • Patients who have received the protocol information and who given their written informed consent.

Who cannot join

  • Contra-indications of MRI
  • Pacemaker or implantable defibrillator,
  • Neurosurgical clips,
  • Cochlear implants,
  • Intra orbital or encephalic metallic foreign bodies,
  • Endoprostheses less than 4 weeks old and osteosynthesis material used within the last 6 weeks,
Show all 9Show fewer
  • Claustrophobia. Contra-indication of FDG-PET
  • Pregnancy
  • Nursing mothers

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU de Rennes

    Rennes, IV, 35033

Other trials in France

About this study

Official title: Study of MRI 3 Tesla Using Arterial Spin Labeling (Without Infusion) in Cognitive Atypical Disorders and Comparison to FDG-PET

DESCRIPTION OF RELATED QUESTION Cognitive disorders are frequently encountered and present a major public health problem given the aging of the population.

There is not one, but several neurodegenerative pathologies individual differentiated.

Read more

Particularly distinguished is Alzheimer's disease (the most common), dementia lobar fronto-temporal associated with semantic dementia (a disease with a particular tropism for semantic memory and the anterior temporal lobe), and dementia with Lewy bodies.

To differentiate these pathologies is, for the clinician, is a major issue and the clinic may not be enough.

The management and current diagnostics of atypical cognitive disorders, that is to say, patients with clinical symptoms or neuropsychological testing results suggestive of a neurodegenerative disorder other than Alzheimer's disease, are based largely on data imaging.

In the first intention, conducting imaging by MRI is recommended by the HAS, particularly to search for treatable causes to these cognitive disorders (tumors, intracranial hemorrhage in particular) but also to study the distribution of cerebral atrophy.

The sequences used are the sequences 3D T1, axial Flair, gradient echo axial T2 and coronal T2 in the plane of hippocampi and also diffusion imaging.

Research has shown interest in the study of cerebral perfusion in cognitive disorders.

The HAS recommends not to inject contrast medium on MRI in this context. The sequence of perfusion by tagging arterial protons or "arterial spin labeling" (ASL) does not use exogenous contrast medium. This is available as a commercial product, CE marked, on most of the recent clinical MRI scanners. This non-invasive technique, requiring no special precautions (e.g. verification of renal function) is used in routine clinical practice at the University Hospital of Rennes and in many centers. In the imaging of patients with dementia, it is widely used as well as the 3D T1 sequences or diffusion imaging (International Initiative ADNI) and is subject to optimization and harmonization of use in routine clinical practice with the European COST AID actions.

The second intention, an isotope imaging by FDG-PET or study of perfusion SPECT can also be performed. The interest of isotopic imaging (FDG-PET and SPECT) lies in the provision of information metabolic nonexistent in MRI, with a superiority of FDG-PET compared with SPECT. FDG-PET is the preferred examination and is carried out at CRLCC Eugène Marquis de Rennes in this context.

The aim of our study is to compare the imaging of TEPFDG, a technique not morphological, and ASL that, even if they do not study the same mode (metabolism for the first and perfusion for the second) may depict consistent anomalies.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. detection of hypoperfusions

    The detection of hypoperfusions with ASL will be performed after quantification of cerebral blood flow by comparison to a template of healthy subjects of the same age.

    A base of imaging data in healthy subjects has already been acquired under another project. Some of this imaging data will be used as comparison data. No healthy subject will be included in the study ASLDEM-DS.

    Measured: less than 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Feb 2014 (estimated)
  2. Study startNov 2012
  3. Primary completionDec 2017
  4. Study completionDec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
1 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02058043
Sponsor's protocol ID
2012-A00147
Other IDs
LOC1202 Gauvrit ASLDEM DS
Acronym
ASLDEM DS
Status last verified
Feb 2018
First submitted
5 Apr 2013
Last updated
19 Feb 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Atypical Cognitive Disorders, run by Rennes University Hospital at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

detection of hypoperfusions (time frame: less than 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in